Pfizer Initiates Phase 2 Clinical Trials in China for Two Trispecific Antibodies PF-07275315 and PF-07264660 in Adults with Moderate-to-Severe Atopic Dermatitis
Pfizer
Pharmaceutical R&D Developer
On July 23, the Chinese Drug Clinical Trial Registration and Information Disclosure Platform showed that Pfizer registered a Phase II clinical trial in China to evaluate PF-07275315 and PF-07264660.In adult subjects with moderate to severe atopic dermatitisThe efficacy and safety. Among them, PF-07275315 isA trispecific antibody targeting IL-4×IL-13×TSLP, PF-07264660 isA trispecific antibody targeting IL-4×IL-13×IL-33。
InterceptImage source:Drug Clinical Trial Registry and Information Disclosure Platform
Atopic Dermatitis (AD) is a common chronic, recurrent, inflammatory skin disease. IL-4 and IL-13 are important cytokines in the pathogenesis of AD, playing a key role in its development.
PF-07275315 and PF-07264660 are two new molecular entities developed by Pfizer and represent important pipelines in Pfizer's inflammation and immunology therapeutic areas. IL-4 and IL-13 are the common targets of these two trispecific antibodies. In addition, PF-07275315 also targets TSLP, an epithelial cell factor that plays a key role in the onset and persistence of airway inflammation. PF-07264660 also targets IL-33, a member of the IL-1 family of cytokines, with potential for treating diseases such as asthma and atopic dermatitis.
Pfizer Plans to Develop These Two Tri-specific Antibody Drugs for the Treatment of Atopic Dermatitis. Overseas, These Two Investigational New Drugs Have Already Entered Phase 2 Clinical Trials.
According to the information from the Chinese Clinical Trial Registry and Information Disclosure Platform, Pfizer has initiated a randomized, double-blind, placebo-controlled Phase 2 clinical study in China. The purpose of the trial is to evaluate the efficacy, safety, and pharmacokinetics of PF-07275315 and PF-07264660.PK) and pharmacodynamics (PD), and to explore the dose-response relationship of PF-07275315 or PF-07264660 in adult study participants with moderate to severe atopic dermatitis.
Inflammation and immunology are very important areas in Pfizer's overall strategy.According to the product pipeline introduction released by Pfizer in October 2023,The pipeline in the field of inflammation and immune diseases currently comprises 17 ongoing projects., including 3 projects in Phase III clinical stage, 11 projects in Phase II clinical stage, and 3 projects in Phase I clinical stage.
In addition to the two aforementioned triple-target antibodies, other products include JAK3/TEC inhibitors, gene therapies, IL-10 antibodies, S1P inhibitors, CXCR5 antibodies, CCR6 antagonists, p40/TL1a bispecific antibodies, and more. The therapeutic areas cover a wide range of indications such as vitiligo, Duchenne muscular dystrophy, ulcerative colitis, Crohn's disease, rheumatoid arthritis, eosinophilic esophagitis, alopecia areata, immune thrombocytopenic purpura, lupus, inflammatory bowel disease, and others.
InterceptImage source: Pfizer Pipeline Introduction PPT
